TY - JOUR
T1 - Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor
T2 - consensus recommendations from the acute leukemia working party of the EBMT
AU - Dholaria, Bhagirathbhai
AU - Savani, Bipin N
AU - Labopin, Myriam
AU - Luznik, Leo
AU - Ruggeri, Annalisa
AU - Mielke, Stephan
AU - Al Malki, Monzr M
AU - Kongtim, Piyanuch
AU - Fuchs, Ephraim
AU - Huang, Xiao-Jun
AU - Locatelli, Franco
AU - Aversa, Franco
AU - Castagna, Luca
AU - Bacigalupo, Andrea
AU - Martelli, Massimo
AU - Blaise, Didier
AU - Ben Soussan, Patrick
AU - Arnault, Yolande
AU - Handgretinger, Rupert
AU - Roy, Denis-Claude
AU - O'Donnell, Paul
AU - Bashey, Asad
AU - Solomon, Scott
AU - Romee, Rizwan
AU - Lewalle, Philippe
AU - Gayoso, Jorge
AU - Maschan, Michael
AU - Lazarus, Hillard M
AU - Ballen, Karen
AU - Giebel, Sebastian
AU - Baron, Frederic
AU - Ciceri, Fabio
AU - Esteve, Jordi
AU - Gorin, Norbert-Claude
AU - Spyridonidis, Alexandros
AU - Schmid, Christoph
AU - Ciurea, Stefan O
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - Copyright © 2019, Ferrata Storti Foundation.
PY - 2019/9/19
Y1 - 2019/9/19
N2 - Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematological relapse, being able to induce durable remissions in a subset of patients. With the increased in the use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post-transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarized the available evidence on the use of donor lymphocyte infusion from haploidentical donor and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.
AB - Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematological relapse, being able to induce durable remissions in a subset of patients. With the increased in the use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post-transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarized the available evidence on the use of donor lymphocyte infusion from haploidentical donor and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.
U2 - 10.3324/haematol.2019.219790
DO - 10.3324/haematol.2019.219790
M3 - Article
JO - Haematologica
JF - Haematologica
SN - 0390-6078
ER -